No Data
Individual stock information.
Silver Life <9262.T> experienced a significant decline. It announced its first half financial results for the fiscal year ending in July, with a standalone operating profit of 443 million yen (a 9.7% decrease compared to the same period last year). The centralization of Logistics hubs has increased in-house shipping, leading to higher costs. The full-year financial estimates remain unchanged, with an expected operating profit of 850 million yen (a 10.6% increase compared to the previous period). The progress rate of the first half operating profit is 52.1%. The company will make Barnibaby <3418.T> Enabidoo a subsidiary (located in Minato, Tokyo). The new subsidiary will focus on regional revitalization in Awaji Island.
Ribomic - last year's high, developed dynamic extension technology in joint research and development with Ajinomoto, patent application.
Last year's high. It has been announced that a technique for prolonging dynamics using antibody Fc domain fusion developed in collaboration with Ajinomoto <2802> has been patented at the Japan Patent Office. This patent relates to conjugates of nucleic acid aptamers and the Fc domain of immunoglobulins, as well as the extension of their blood half-life, which has the potential to drastically improve the pharmacokinetics of next-generation Pharmaceuticals using nucleic acid aptamers instead of conventional polyethylene glycol (PEG) modification techniques.
Ribomic surges to last year's high, seen as a material related to patent application.
Ribomic <4591.T> surged sharply. At one point, it rose by 30 yen to 136 yen, significantly updating the last year's high of 124 yen on February 19. After the market closed on the 11th, it was announced that a patent application regarding the conjugate of nucleic acid aptamers and the Fc region of immunoglobulin, as well as its blood half-life extension, was filed with Japan's Patent Office, which was seen as a material factor. The company is conducting joint research aimed at realizing next-generation aptamer Pharmaceuticals in collaboration with Ajinomoto <2802.T>. The technology for which the patent has been applied is a conventional poly.
Ribomic, Barunibabi, and others.
Acquired shares of Enabiru Doo, which engages in the sale, rental, management, Shareholding, and disposal of Valuni Babi A-REIT ETF <3418>. Completed the development and patent application of the antibody Fc domain fusion-based pharmacokinetic extension technology in collaboration with Ajinomoto <2802> and Ribomic <4591>. Eco Leather, a consolidated subsidiary of Technologies <5248>, has formed a business alliance with West Holdings <1407>. Issued new shares through third-party allocation (2.75 million shares) in the 4th new share subscription by ispace <9348>.
Japanese stock buybacks this week (3/3~3/7)
――――3/3――――$Amiya(4258.JP)$ will buy back up to 100K shares, 2.42% of its outstanding shares (excluding its own shares), for an amount of JPY¥ 300 million.$Mizuho Financial Group(8411.JP)$ will
Ajinomoto: Extraordinary Report
